Krystal Biotech Receives FDA Approval for the First-Ever Redosable Gene Therapy, VYJUVEK™…
<!-- Name:DistributionId Value:8843111 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4573 -->…
Browsing Tag
Bullosa
Krystal Biotech erhält positive Stellungnahme des Pädiatrieausschusses der EMA hinsichtlich des…
• Das Unternehmen befindet sich im Zeitplan, um im vierten Quartal 2022 einen Zulassungsantrag für Europa zu stellen • Es sind keine weiteren Studien erforderlich PITTSBURGH, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech,…
Krystal Biotech Receives Positive Opinion from EMA Pediatric Committee on the Pediatric…
• Company on track to submit European marketing application in Q4 2022 • No additional studies required PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), the leader in redosable gene…
FDA Accepts Krystal Biotech’s Biologics License Application for Dystrophic Epidermolysis Bullosa
FDA granted Priority Review designationPDUFA target action date is February 17, 2023FDA stated that it is not currently planning to hold an advisory committee meeting PITTSBURGH, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech,…
Abeona Therapeutics Announces Support of EB Research Partnership’s Venture Into Cures Event to…
NEW YORK and CLEVELAND, Nov. 18, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced its sponsorship of the second annual Venture Into Cures, a virtual…
Abeona Therapeutics Activates Second Clinical Trial Site in EB-101 Pivotal Phase 3 VIITAL™ Study for…
NEW YORK and CLEVELAND, July 23, 2021 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the activation of a second clinical trial site in its pivotal Phase 3…
DelveInsight Highlights Major Advances, Transformative Therapies and Leading Players Wheeling the…
Los Angeles, USA, June 30, 2021 (GLOBE NEWSWIRE) -- DelveInsight Highlights Major Advances, Transformative Therapies and Leading Players Wheeling the Dystrophic Epidermolysis Bullosa Pipeline Landscape The Dystrophic Epidermolysis…